Literature DB >> 16175176

Opinion: how patients have benefited from mouse models of acute promyelocytic leukaemia.

Valérie Lallemand-Breitenbach1, Jun Zhu, Scott Kogan, Zhu Chen, Hugues de Thé.   

Abstract

One of the challenges of studying anticancer therapies is that effects observed in cell lines or mouse models are not always good indicators of clinical trial results. The mouse model of acute promyelocytic leukaemia has bucked this trend, as targeted therapies such as retinoic acid and arsenic induce differentiation and clearance of leukaemia cells in both mice and humans. This mouse model has also provided important mechanistic insights into the combinatorial effects of these agents and has promoted combined therapies that have shown recent success in the clinic.

Entities:  

Mesh：

Year:  2005        PMID： 16175176     DOI： 10.1038/nrc1719

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


  10 in total

1.  Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting.

Authors:  Rihab Nasr; Hugues de Thé
Journal:  Int J Hematol       Date:  2010-05-11       Impact factor: 2.490

Review 2.  [Malignancy potential of precursor lesions: determination using molecular markers].

Authors:  A Jung
Journal:  Pathologe       Date:  2011-11       Impact factor: 1.011

3.  Aberrant chromatin remodeling by retinoic acid receptor alpha fusion proteins assessed at the single-cell level.

Authors:  Jihui Qiu; Ying Huang; Guoqiang Chen; Zhu Chen; David J Tweardy; Shuo Dong
Journal:  Mol Biol Cell       Date:  2007-08-01       Impact factor: 4.138

Review 4.  Acute promyelocytic leukaemia: novel insights into the mechanisms of cure.

Authors:  Hugues de Thé; Zhu Chen
Journal:  Nat Rev Cancer       Date:  2010-10-22       Impact factor: 60.716

5.  Finding a needle in a haystack: whole genome sequencing and mutation discovery in murine models.

Authors:  Raajit K Rampal; Ross L Levine
Journal:  J Clin Invest       Date:  2011-03-23       Impact factor: 14.808

Review 6.  How animal models of leukaemias have already benefited patients.

Authors:  Julien Ablain; Rihab Nasr; Jun Zhu; Ali Bazarbachi; Valérie Lallemand-Breittenbach; Hugues de Thé
Journal:  Mol Oncol       Date:  2013-02-11       Impact factor: 6.603

7.  ASB2 targets filamins A and B to proteasomal degradation.

Authors:  Mélina L Heuzé; Isabelle Lamsoul; Massimiliano Baldassarre; Yatish Lad; Sophie Lévêque; Ziba Razinia; Christel Moog-Lutz; David A Calderwood; Pierre G Lutz
Journal:  Blood       Date:  2008-09-17       Impact factor: 22.113

Review 8.  The cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodies.

Authors:  Hugues de Thé; Morgane Le Bras; Valérie Lallemand-Breitenbach
Journal:  J Cell Biol       Date:  2012-07-09       Impact factor: 10.539

Review 9.  Mechanisms of Microbe-Host Interaction in Crohn's Disease: Dysbiosis vs. Pathobiont Selection.

Authors:  Ludovica F Buttó; Monika Schaubeck; Dirk Haller
Journal:  Front Immunol       Date:  2015-11-19       Impact factor: 7.561

Review 10.  Acute Promyelocytic Leukemia: A Constellation of Molecular Events around a Single PML-RARA Fusion Gene.

Authors:  Alessandro Liquori; Mariam Ibañez; Claudia Sargas; Miguel Ángel Sanz; Eva Barragán; José Cervera
Journal:  Cancers (Basel)       Date:  2020-03-08       Impact factor: 6.639
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.